

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



## **EXTRAWELL PHARMACEUTICAL HOLDINGS LIMITED**

**精優藥業控股有限公司\***

*(Incorporated in Bermuda with limited liability)*

**(Stock Code: 00858)**

### **PROFIT WARNING**

This announcement is made by Extrawell Pharmaceutical Holdings Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) pursuant to Rule 13.09 of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “**Listing Rules**”) and the Inside Information Provisions (as defined in the Listing Rules) under Part XIVA of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong).

The board of directors of the Company (the “**Board**”) wishes to inform the shareholders of the Company (the “**Shareholders**”) and potential investors that based on the preliminary assessment of the unaudited consolidated management accounts of the Group for the six months ended 30 September 2023 (the “**Management Accounts**”), the Group expects to record a loss in the range between HK\$235 million and HK\$240 million, as compared to a profit of approximately HK\$46 million for the six months ended 30 September 2022. The expected turnaround from profit to loss in the current period was primarily attributable to the non-cash item resulted from the fair value change (loss) of the financial assets at fair value through profit or loss i.e. the Group’s investments in convertible bonds, while a fair value change (gain) was recorded in the corresponding period of 2022.

The Company is still in the process of preparing the interim results of the Group for the six months ended 30 September 2023, the information as set out above is only based on the preliminary assessment by the Board on the information currently available to it, including the Management Accounts, which have yet to be confirmed. The unaudited consolidated interim results of the Group for the six months ended 30 September 2023 are expected to be published before the end of November 2023.

**Shareholders and potential investors are advised to exercise caution when dealing in the shares of the Company.**

By order of the Board  
**Extrawell Pharmaceutical Holdings Limited**  
**Xie Yi**  
*Chairman*

Hong Kong, 10 November 2023

*As at the date of this announcement, the executive directors are Dr. Xie Yi, Mr. Cheng Yong, Dr. Lou Yi and Ms. Wong Sau Kuen, and the independent non-executive directors are Mr. Fang Lin Hu, Ms. Jin Song and Dr. Guo Yi.*

\* *For identification purpose only*